RGH-706 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 193 | プラダー・ウィリ症候群 | 1 |
193. プラダー・ウィリ症候群
臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05322096 (ClinicalTrials.gov) | September 22, 2022 | 25/3/2022 | Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome | A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: RGH-706;Drug: Placebo | Gedeon Richter Plc. | NULL | Recruiting | 17 Years | N/A | All | 176 | Phase 2 | United States;Czechia;France;Italy;Spain |